MedTrace Logo

Comparative Bioavailability in Healthy Elderly Volunteers

NCT01253122 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2010-12-03

No results posted yet for this study

Summary

A randomised four way crossover design in which each subject will receive two dose levels of TRx-0037 and two doses of TRx-0014 over approximately a four week period in randomised order.

Conditions

Interventions

DRUG

TRx0037

Sponsors & Collaborators

  • Quotient Clinical

    collaborator OTHER

  • TauRx Therapeutics Ltd

    lead INDUSTRY

Principal Investigators

  • Stuart Dr Mair, MBChB · Quotient Clinical

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2010-04-30
Completion
2010-04-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01253122 on ClinicalTrials.gov